Literature DB >> 32220902

Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.

Hannes Hagström1,2,3, Maja Thiele4, Bjorn Roelstraete5, Jonas Söderling5, Jonas F Ludvigsson5,6,7,8.   

Abstract

OBJECTIVE: Patients with alcohol-related liver disease (ALD) are at increased risk of death, but studies have rarely investigated the significance of histological severity or estimated relative risks compared with a general population. We examined mortality in a nationwide cohort of biopsy-proven ALD.
DESIGN: Population-based cohort study in Sweden comparing 3453 individuals with an International Classification of Disease (ICD) code for ALD and a liver biopsy from 1969 to 2017 with 16 535 matched general population individuals. Swedish national registers were used to ascertain overall and disease-specific mortality, starting follow-up at the latest of first ICD diagnosis or liver biopsy plus 3 months. Cox regression adjusted for relevant confounders was used to estimate HRs in ALD and histopathological subgroups.
RESULTS: Median age at diagnosis was 58 years, 65% were men and 52% had cirrhosis at baseline. Five-year cumulative mortality was 40.9% in patients with ALD compared with 5.8% in reference individuals. The risk for overall mortality was significantly increased (adjusted HR (aHR)=4.70, 95% CI 4.35 to 5.08). The risk of liver-related death was particularly high (43% of all deaths, aHR=167.6, 95% CI 101.7 to 276.3). Mortality was significantly increased also in patients with ALD without cirrhosis and was highest in the first year after baseline but persisted after ≥10 years of follow-up (aHR=2.74, 95% CI 2.37 to 3.16).
CONCLUSION: Individuals with biopsy-proven ALD have a near fivefold increased risk of death compared with the general population. Individuals with ALD without cirrhosis were also at increased risk of death, reaffirming the need to increase vigilance in the management of these individuals. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  alcoholic liver disease; epidemiology; ethanol

Mesh:

Year:  2020        PMID: 32220902     DOI: 10.1136/gutjnl-2019-320446

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES).

Authors:  Young Kyung Ko; Hayeon Kim; Yoonseok Lee; Young-Sun Lee; Jeong-An Gim
Journal:  Curr Issues Mol Biol       Date:  2022-02-27       Impact factor: 2.976

2.  The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study.

Authors:  Bonnie Bengtsson; Linnea Widman; Staffan Wahlin; Per Stål; Niklas K Björkström; Hannes Hagström
Journal:  United European Gastroenterol J       Date:  2022-05-01       Impact factor: 6.866

3.  Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality.

Authors:  Sónia Bernardo; Ricardo Crespo; Sofia Saraiva; Rui Barata; Sara Gonçalves; Paulo Nogueira; Helena Cortez-Pinto; Mariana Verdelho Machado
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

4.  Incidence of ICD-Based Diagnoses of Alcohol-Related Disorders and Diseases from Swedish Nationwide Registers and Suggestions for Coding.

Authors:  David Bergman; Hannes Hagström; Andrea Johansson Capusan; Karl Mårild; Fredrik Nyberg; Kristina Sundquist; Jonas F Ludvigsson
Journal:  Clin Epidemiol       Date:  2020-12-31       Impact factor: 4.790

5.  Corrigendum to 'Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis' [JHEP Reports 3 (2021) 100287].

Authors:  Nikolaj Torp; Mads Israelsen; Bjørn Madsen; Philipp Lutz; Christian Jansen; Christian Strassburg; Christian Mortensen; Anne Wilkens Knudsen; Grith Lykke Sorensen; Uffe Holmskov; Anders Schlosser; Maja Thiele; Jonel Trebicka; Aleksander Krag
Journal:  JHEP Rep       Date:  2021-08-27

6.  Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease.

Authors:  Hannes Hagström; Maja Thiele; Tracey G Simon; Rajani Sharma; Anna Röckert Tjernberg; Bjorn Roelstraete; Jonas Söderling; Jonas F Ludvigsson
Journal:  United European Gastroenterol J       Date:  2022-01-28       Impact factor: 4.623

7.  Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation.

Authors:  Maja Thiele; Stine Johansen; Natasja S Gudmann; Bjørn Madsen; Maria Kjaergaard; Mette Juul Nielsen; Diana J Leeming; Suganya Jacobsen; Flemming Bendtsen; Søren Møller; Sönke Detlefsen; Morten Karsdal; Aleksander Krag
Journal:  Aliment Pharmacol Ther       Date:  2021-08-24       Impact factor: 9.524

8.  Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist.

Authors:  Seung-Hee Lee; Vimal Veeriah; Fred Levine
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

9.  Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis.

Authors:  Nikolaj Torp; Mads Israelsen; Bjørn Madsen; Philipp Lutz; Christian Jansen; Christian Strassburg; Christian Mortensen; Anne Wilkens Knudsen; Grith Lykke Sorensen; Uffe Holmskov; Anders Schlosser; Maja Thiele; Jonel Trebicka; Aleksander Krag
Journal:  JHEP Rep       Date:  2021-03-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.